Trial Profile
Comparison of efficacy of standard (48 weeks) against extended (72 weeks) Peginterferon Alfa-2a therapy in Chinese patients with HBeAg-Negative Chronic Hepatitis B
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Oct 2015
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 08 Oct 2015 New trial record